Provided by Tiger Trade Technology Pte. Ltd.

Avis Budget

140.70
-6.7900-4.60%
Post-market: 141.270.5700+0.41%18:10 EDT
Volume:298.90K
Turnover:42.15M
Market Cap:4.97B
PE:-7.84
High:146.77
Open:146.77
Low:138.82
Close:147.49
52wk High:847.70
52wk Low:85.96
Shares:35.32M
Float Shares:14.85M
Volume Ratio:0.72
T/O Rate:2.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-17.9408
EPS(LYR):-25.2557
ROE:5800.00%
ROA:2.70%
PB:-1.47
PE(LYR):-5.57

Loading ...

How Early Allogeneic CAR T Results At CARsgen (SEHK:2171) Have Changed Its Investment Story

Simply Wall St.
·
Jun 19

Movement Alert|Avis Budget Group Rises 5.32% in Regular Trading, Trading at $189.8

Market Focus
·
Jun 19

Bristol Myers Squibb (BMY) Reports Strong Myeloma Trial Results And Early CAR T Progress

Simply Wall St.
·
Jun 18

CARsgen Therapeutics Holdings (SEHK:2171) Stock Looks Rich Even After New CAR T Data

Simply Wall St.
·
Jun 16

Legend Biotech Unveils Strong First-in-Human Data for In Vivo CAR-T LB2501 at EHA 2026

TIPRANKS
·
Jun 15

Legend Biotech Says In Vivo CAR-T Candidate LB2501 Delivers Early Proof-of-Concept in Lymphoma

MT Newswires Live
·
Jun 15

Park24 to Reintroduce Shareholder Benefits Tied to Times CAR Service

TIPRANKS
·
Jun 15

CARsgen Advances Allogeneic CAR T Programs After Positive Early Data at EHA 2026

TIPRANKS
·
Jun 15

Legend Biotech announces first clinical proof-of-concept data for LB2501

TIPRANKS
·
Jun 15

GenScript Associate Legend Biotech Reports Promising In Vivo CAR-T Data in B-Cell Lymphoma

TIPRANKS
·
Jun 14

Genscript Biotech's Affiliate Reports Proof of Concept for Novel In Vivo Dual-Target CAR-T Therapy in Lymphoma

Stock News
·
Jun 14

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

GlobeNewswire
·
Jun 14

Avis Budget Issues New Asset-Backed Securities for Fleet Funding

TIPRANKS
·
Jun 13

Avis Budget unit issues USD 650 million in vehicle-backed notes under AESOP program

Reuters
·
Jun 13

Caribou Biosciences: Buy Rating Reaffirmed on Advancing Allogeneic CAR-T Pipeline and EHA Data; $6 Price Target Maintained

TIPRANKS
·
Jun 12

Caribou Biosciences presents ANTLER trial results at EHA

TIPRANKS
·
Jun 11

Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting

GlobeNewswire
·
Jun 11

Cellectis Unveils Strong Early CAR-T Data for Lasme-cel and Eti-cel at EHA 2026

TIPRANKS
·
Jun 11

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

GlobeNewswire
·
Jun 11

Verra Mobility Faces Federal Securities Lawsuit After 71% Stock Drop Following Avis Budget Group Termination Notice

TIPRANKS
·
Jun 11